TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer

All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set…

Details

TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference

Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by…

Details

SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million

New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (TPIV). “We are very pleased by the recent $2M raise as it will help TapImmune proceed…

Details

TapImmune’s New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens

SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are…

Details

TapImmune Prevails in Legal Dispute with Michael Gardner

International Arbitration Tribunal Finds in Favor of TapImmune Inc., and Awards the Company $196,204 in Damages SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation. The International Center for Dispute Resolution International Arbitration Tribunal has found that Mr. Gardner made numerous false representations, did not…

Details